Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07000110

Anifrolumab Malignancy and Serious Infections Study

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

Official title: A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab

Key Details

Gender

All

Age Range

18 Years - 130 Years

Study Type

OBSERVATIONAL

Enrollment

3195

Start Date

2026-01-26

Completion Date

2031-11-30

Last Updated

2026-03-24

Healthy Volunteers

No

Interventions

DRUG

Anifrolumab

Anifrolumab prescribed per local practice

Locations (4)

Research Site

Copenhagen, Denmark

Research Site

Charenton-le-Pont, France

Research Site

Essen, Germany

Research Site

Barcelona, Spain